Business Wire

CA-QVEST-GROUP

8.12.2020 20:52:10 CET | Business Wire | Press release

Share
Qvest Group Acquires OnPrem Solution Partners LLC

The Qvest Group, a world-leading systems architect and ICT integrator, today announced the acquisition of the majority of OnPrem Solution Partners LLC, a highly reputed consultancy across the media and entertainment supply chain in the USA. OnPrem’s expertise in business and technology consulting, especially its focus on the digital media supply chain, will complement and extend the Qvest Group’s portfolio and lay the foundation to gain a foothold on the US-American market.

Headquartered in Los Angeles, with additional offices in New York and Austin, OnPrem is an end-to-end solution provider that strategizes, advises, designs and develops technology solutions, leveraging their expertise in content, customers and data for media and entertainment and consumer products industries. The acquisition brings a highly experienced team of more than 250 consultants to deliver solutions in areas such as Digital Media Supply Chain, IP and Rights Management, Data and Analytics, Customer Experience Design, Salesforce and Program Management/PMO to the Qvest Group. OnPrem has built dynamic partnerships with leading technology providers and platforms such as AWS, Salesforce and Microsoft.

“OnPrem strengthens the position of the Qvest Group as a leading partner in digital media, data and cloud management and considerably enhances our capacity to provide clients with added value, scale, and world-class expertise,” said Peter Nöthen, CEO of the Qvest Group. “For Qvest, this is also the steppingstone to the largest market for broadcast & media in the world which significantly raises our international business in technology consultancy and systems integration. Moreover, joining forces with OnPrem enables us to better and directly support worldwide operating clients and it also generates the ground for the growth of our cloud management platform qibb in the US-American market.”

Frank Leal, Partner at OnPrem, agrees: “The leadership at OnPrem is excited and inspired by our new Qvest partnership. With Qvest’s focus on the media industry and quality and their international presence, there was no better fit for us. This transaction creates a worldwide entity that is a partner to CTOs, CIOs and Broadcast Engineers everywhere. Most importantly, we were able to join a leadership team with a similar philosophy on culture and talent, providing additional opportunities for our team members and creating an organization that is a home to the best consultants and engineers in the world.”

The Qvest Group, headquartered in Germany, has offices across Europe, the Middle East, APAC, and Australia. The company has been accelerating the digital transformation of its clients, offering capabilities in technology design consultancy and systems integration, software development, cloud engineering, and technical infrastructure operations.

For OnPrem, Qvest’s service offerings and global scale will help to meet its clients’ growing needs for architecture design, seamless technology integration and realizing large-scaled media infrastructure projects along the entire digital media value chain.

As part of the acquisition, the Qvest Group acquired 55 % of the shares in OnPrem. The contract was signed on December 2, 2020. The partners at OnPrem, Frank Leal, Candice Lu, Christophe Ponsart, Jon Christian, and Vanessa Fiola, along with leadership will continue to build on its long-standing, valued relationships with employees and clients.

About Qvest Group

Qvest is a world-leading systems architect, consultant and ICT integrator in the innovation-driven media industry. The company’s range of services is aligned to the opportunities emerging from an increasingly digital media value chain such as multi-platform content delivery, AI, big data analysis, multi-cloud management and IP infrastructures. Qvest Media’s clients include renowned media networks, telecommunication providers, broadcasters, companies and organizations from the industrial and public sector. Next to the headquarters in Cologne, Qvest Media operates further locations in Europe, the USA, MENA & APAC.

www.qvestmedia.com

About OnPrem

OnPrem Solution Partners is an end-to-end solution provider that strategizes, advises, designs, develops and integrates world-class technology. Experts in Digital Media Supply Chain, IP and Rights Management, CRM, AI, Data & Analytics, PMO/Project management and custom development, OnPrem connects disparate parts of an organization to enable operational excellence. Based in Los Angeles with offices in New York and Austin Texas, OnPrem offers its expertise within the Media & Entertainment, Consumer Packaged Goods industries and more.

www.onprem.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye